<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        128-368-12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOZAL 5 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOCETIRIZINE DIHYDROCHLORIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        OTC
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        20.50
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        R06AE09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Levocetirizine dihydrochloride is the active ingredient of Levozal&trade;.<br />Levozal&trade; is an antiallergic medication. It is used for the treatment of<br />signs of illness (symptoms) associated with:<br />&bull; allergic rhinitis (including persistent allergic rhinitis);<br />&bull; nettle rash (urticaria).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Levozal&trade;<br />&bull; if you are allergic (hypersensitive) to levocetirizine dihydrochloride<br />or to an antihistamine or any of the other ingredients of Levozal&trade;<br />(see &lsquo;What Levozal&trade; contains&rsquo;).<br />&bull; if you have a severe impairment of kidney function (severe renal<br />failure with creatinine clearance below 10 ml/min).<br />Take special care with Levozal&trade;<br />The use of Levozal&trade; is not recommended in children less than 6<br />years since the film-coated tablets do not allow for dose adaptation.<br />Taking other medicines<br />Please tell your doctor or pharmacist if you are taking or have<br />recently taken any other medicines, including medicines obtained<br />without a prescription.<br />Taking Levozal&trade; with food and drink<br />Caution is advised if Levozal&trade; is taken at the same time as alcohol.<br />In sensitive patients, the simultaneous use of cetirizine or<br />levocetirizine and alcohol or other centrally acting agents may have<br />effects on the central nervous system, although the racemate<br />cetirizine has been shown not to increase the effect of alcohol.</p><p>Pregnancy and breast-feeding<br />Ask your doctor or pharmacist for advice before taking any<br />medicine. Tell your doctor if you are pregnant, trying to get pregnant<br />or breast-feeding.<br />Driving and using machines<br />Some patients being treated with Levozal&trade; may experience<br />somnolence / drowsiness, tiredness and exhaustion. If you are<br />intending to drive, engage in potentially hazardous activities or use<br />machines you are therefore advised first to wait and observe your<br />response to the medication. However, special tests have revealed no<br />impairment of mental alertness, the ability to react or the ability to<br />drive in healthy test persons after taking levocetirizine in the<br />recommended dosage.<br />Important information about some of the ingredients of<br />Levozal&trade;<br />These tablets contain lactose, if you have been told by your doctor<br />that you have an intolerance to some sugars you should contact your<br />doctor before taking them.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take Levozal&trade; exactly as your doctor has told you. You<br />should check with your doctor or pharmacist if you are not sure. The<br />usual dose for adults and children aged 6 years and over is one tablet<br />daily.<br />Special dosage instructions for specific populations:<br />Patients with impaired kidney function may be given a lower dose<br />according to the severity of their kidney disease. Patients who only<br />have impaired liver function should take the usual prescribed dose.<br />Patients who have both impaired liver and kidney function may be<br />given a lower dose depending on the severity of the kidney disease,<br />and in children the dose will also be chosen on the basis of body<br />weight; the dose will be determined by your doctor. Levozal&trade; is not<br />recommended for children under 6 years of age.<br />How and when should you take Levozal&trade;?<br />The tablets should be swallowed whole with water and may be taken<br />with or without food.<br />If you take more Levozal&trade; than you should<br />A substantial overdose may cause somnolence in adults. Children<br />may initially show excitation and restlessness followed by<br />somnolence. If you think you have taken an overdose of Levozal&trade;,<br />please tell your doctor who will then decide what action should be<br />taken.<br />If you forget to take Levozal&trade;<br />If you forget to take Levozal&trade;, or if you take a dose lower than that<br />prescribed by your doctor, do not take a double dose to compensate;</p><p>just wait for the foreseen time for intake of the next dose, and take a<br />normal dose as prescribed by your doctor.<br />If you stop taking Levozal&trade;<br />Stopping the treatment with Levozal&trade; earlier than foreseen should<br />have no detrimental effects, in the sense that the symptoms of the<br />disease should just progressively reappear with a severity not higher<br />than the one experienced prior to treatment with Levozal&trade;. If you<br />have any further questions on the use of this product, ask your doctor<br />or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Levozal&trade; can cause side effects, although not<br />everybody gets them. Commonly (1% to 10%), mainly mild to<br />moderate side effects such as dry mouth, headache, tiredness and<br />somnolence/drowsiness have been reported. Uncommon (0.1% to<br />1%), side effects such as exhaustion and abdominal pain have been<br />observed. Other side effects such as palpitations, increased heart rate,<br />convulsions, visual disturbances, oedema, pruritus (itchiness), rash,<br />urticaria (swelling, redness and itchiness of the skin), skin eruption,<br />shortness of breath, weight increase, muscular pain, aggressive or<br />agitated behaviour, hallucination, depression, hepatitis, abnormal<br />liver function, nausea and vomiting have also been reported. At the<br />first signs of a hypersensitivity reaction, stop taking Levozal&trade; and<br />see your doctor immediately. Hypersensitivity reaction symptoms<br />may include: swelling of the mouth, tongue, face and/or throat,<br />breathing or swallowing difficulties together with hives<br />(angioedema), sudden fall in blood pressure leading to collapse or<br />shock, which may be fatal.<br />If any of the side effects gets serious, or if you notice any side effects<br />not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the reach and sight of children.<br />&bull; Do not store above 30 &deg;C. In a dry place.<br />&bull; Do not use Levozal&trade; after the expiry date which is stated on the<br />carton after Exp.<br />&bull; Medicines should not be disposed of via waste water or household<br />waste. Ask your pharmacist how to dispose of medicines no longer<br />required. This will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Levozal&trade; contains<br />- The active substance is levocetirizine dihydrochloride.<br />Each film-coated tablet contains 5 mg levocetirizine dihydrochloride.<br />- The other ingredients are lactose anhydrous, microcryastalline<br />cellulose (PH 102), colloidal silicone dioxide (Aerosil 200),<br />magnesium stearate and opadry white.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Levozal™ looks like and contents of the pack
• Levozal™ 5 mg film-coated tablets are off-white, round, biconvex,
engraved with 'JP89' on one side and plain on other side.
• Levozal™ 5 mg is available in a pack of 20 film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Jamjoom Pharmaceuticals Co., Ltd., Jeddah, Saudi Arabia.<br />Tel: +966-2-6081111, Fax: +966-2-6081222.<br />Website: www.jamjoompharma.com<br />To report any side effect(s):<br />&bull; Saudi Arabia:<br />National Pharmacovigilance Center (NPC)<br />Fax: +966-11-205-7662<br />E-mail: npc.drug@sfda.gov.sa, Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                02/2013
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ليڤوزال ليفوستيريزين داي هيدروكلوريد هى المادة الفعالة الموجودة فى<br />&trade; ليڤوزال هو دواء مضاد للحساسية يستخدم لعلاج الأعراض المصاحبة ل:<br />&bull; التهاب الأنف التحسسى (بما فيها حساسية الأنف المستمرة).<br />&bull; طفح القُرّاص (طفح جلدى).</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />&trade; لا تتناول ليڤوزال فى الحالات الآتية:<br />&bull; إذا كنت تعانى من حساسية مفرطة لمادة ليفوستيريزين داي هيدروكلوريد أو أى من<br />المكونات الأخرى لهذا الدواء (أنظر إلى الجزء ٦ الذى يحمل عنوان &quot;ما هي مكونات<br />. (&quot;&trade; ليڤوزال<br />&bull; إذا كان لديك خلل شديد فى وظائف الكلى (فشل كلوى حاد مع تصفية كرياتينين أقل<br />من ۱۰ مل فى الدقيقة).<br />&trade; أعط عناية خاصة عند تناول ليڤوزال<br />&trade; لا يوصى باستخدام ليڤوزال للأطفال أقل من ٦ سنوات حيث أن الأقراص المغلفة<br />لا يمكن تعديل جرعتها لتناسب الأطفال.<br />تناول أدوية أخرى<br />يرجى إخبار الطبيب أو الصيدلى إذا كنت تتناول أو تناولت مؤخرا أي أدوية أخرى.<br />هذا يشمل الأدوية التى يمكنك شراؤها بدون تذكرة طبية.<br />&trade; تناول ليڤوزال مع الطعام و الشراب<br />فى نفس الوقت مع الكحول. فى الأشخاص &trade; يجب توخى الحذر إذا ما أُّخذ ليڤوزال<br />الذين يعانون من الحساسية، الاستخدام المتزامن لسيتريزين أو ليڤوسيتريزين مع<br />الكحول أو الأدوية الأخرى التى تؤثر على الجهاز العصبى المركزى قد يكون له تأثير<br />على الجهاز العصبى المركزى.<br />الحمل و الرضاعة<br />استشيرى الطبيب أو الصيدلى قبل أن تتناولى أى دواء. اخبرى طبيبك انك حاملا،<br />تحاولين أن تصبحي حاملا أو انك مرضع</p><p>قيادة المركبات و تشغيل الآلات<br />&nbsp;&trade; بعض الأشخاص الذين يستخدمون ليڤوزال قد يشعرون بالنعاس، الدوار ، التعب و<br />الإرهاق.<br />إذا كنت تنوى القيادة ، المشاركة فى أنشطة خطرة أو تشغيل آلات يجب عليك أن<br />تنتظر لتلاحظ تأثير هذا الدواء عليك. بالرغم من ذلك، بعض الفحوصات الخاصة<br />أظهرت انه لا يوجد تأثير على اليقظة الذهنية أو على القدرة على القيادة فى<br />الأشخاص الأصحاء بعد تناول ليڤوسيتريزين فى الجرعة الموصى بها.<br />&trade; معلومة هامة عن بعض مكونات ليڤوزال<br />هذه الأقراص تحتوى على اللاكتوز . إذا ما تم إخبارك بأنه لا يمكنك هضم بعض<br />السكريات ، تحدث إلى طبيبك قبل البدء فى تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><br />&nbsp;&trade; قم دائما بتناول ليڤوزال كما أخبرك طبيبك تماما. يجب عليك مراجعة الطبيب أو<br />الصيدلى إذا كنت غير متأكد من طريقة الاستخدام .<br />الجرعة المعتادة للكبار و الأطفال من سن ٦ سنوات و أكبر هى قرص واحد مرة<br />يوميا.<br />تعليمات خاصة للجرعة لبعض الأشخاص:<br />الأشخاص الذين يعانون من خلل فى وظائف الكلى قد يوصف لهم جرعة أقل وفقا<br />لمدى شدة مرض الكلى لديهم.<br />الأشخاص الذين يعانون فقط من خلل فى وظائف الكبد يجب أن يتناولوا الجرعة<br />المعتادة الموصوفة لهم.<br />الأشخاص الذين يعانون من خلل فى وظائف الكبد و الكلى معا قد يوصف لهم جرعة<br />أقل وفقا لمدى شدة مرض الكلى لديهم.<br />سوف يقوم الطبيب بتحديد الجرعة للأطفال بناءا على وزن جسم الطفل.<br />للأطفال أقل من ٦ سنوات. &trade; لا يوصى باستخدام ليڤوزال<br />؟&trade; كيف و متى تتناول ليڤوزال<br />يجب بلع الأقراص كاملة مع الماء و يمكن تناولها مع أو بدون الطعام.<br />أكثر مما ينبغى: &trade; إذا كنت تتناول ليڤوزال<br />فى الكبار الجرعة الزائدة تسبب الشعور بالنعاس.<br />فى الأطفال الجرعة الزائدة فى البداية تسبب الإستثارة و الأرق ثم الشعور بالنعاس.<br />من فضلك قم باخبار الطبيب ،&trade; إذا كنت تشك انك تناولت جرعة زائدة من ليڤوزال<br />الذى سوف يقرر ما الذى يجب فعله.<br />&trade; إذا نسيت أن تتناول ليڤوزال<br />أو تناولت جرعة أقل من الموصوفة لك، لا تتناول &trade; إذا نسيت أن تتناول ليڤوزال<br />جرعة مضاعفة لتعويض ذلك ، فقط انتظر موعد الجرعة التالية و خذ جرعتك العادية<br />كما هو موصوف لك من قبل طبيبك.<br />&trade; إذا توقفت عن تناول ليڤوزال<br />قبل الموعد المحدد لذلك ليس له أى آثار ضارة إلا أن &trade; إيقاف العلاج بليڤوزال<br />أعراض المرض تبدأ فى الظهور تدريجيا مرة أخرى و شدتها لا تزيد عن شدة هذه<br />.&trade; الأعراض قبل العلاج بليڤوزال<br />إذا كان لديك أية أسئلة أخرى عن استخدام هذا الدواء ، إسأل الطبيب أو الصيدلى .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>٤. الآثار الجانبية المحتملة<br />&trade; كما هو الحال مع جميع الأدوية ، من المحتمل ظهور أعراض جانبية مع ليڤوزال<br />لكنها لا تصيب كل الأشخاص.<br />(٪ أعراض جانبية شائعة ( ۱ إلى ۱۰<br />غالبا ما تكون خفيفة إلى متوسطة الحدة مثل جفاف الفم، صداع، إرهاق و نعاس.<br />(٪ أعراض جانبية غير شائعة ( ۰٫۱ إلى ۱<br />الشعور بالإرهاق و ألم البطن.<br />أعراض جانبية أخرى<br />خفقان، زيادة معدل ضربات القلب، تشنجات، إضطرابات بصرية، وذمة، حكة، طفح<br />جلدى، شرى (تورم، إحمرار و حكة فى الجلد)، ضيق التنفس، زيادة الوزن، ألم فى<br />العضلات، إضطراب و عدوانية السلوك، هلوسة، إكتئاب، إلتهاب الكبد، إضطراب<br />وظائف الكبد، غثيان و قىء .<br />&trade; توقف عن تناول ليڤوزال مع ظهور أول علامات الإصابة بفرط الحساسية و توجه<br />إلى طبيبك على الفور.<br />أعراض الإصابة بفرط الحساسية تشمل: تورم الفم، اللسان، الوجه و/أو الحلق،<br />صعوبة فى البلع أو التنفس مصاحب لها طفح جلدى (وذمة وعائية)،إنخفاض مفاجىء<br />فى ضغط الدم مما يؤدى إلى صدمة أو فقدان الوعى و قد يكوم هذا خطيرا.<br />إذا وصلت أحد الآثار الجانبية لهذا الدواء لمرحلة الخطر أو ظهرت آثار جانبية جديدة<br />لم تذكر في هذه النشرة يرجى اخبار الطبيب ، الصيدلي أوالممرضة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٥. كيف تقوم بحفظ ليڤوزال<br />&bull; يحفظ بعيداً عن متناول و مرأى الأطفال.<br />&bull; يحفظ في درجة حرارة لا تزيد عن ۳۰ درجة مئوية. في مكان جاف.<br />&trade; &bull; لا تقم بإستخدام ليڤوزال بعد انتهاء تاريخ الصلاحية المطبوع على العبوة من<br />الخارج.<br />&bull; لا يتم التخلص من الأدوية عن طريق مياه الصرف أو النفايات المنزلية. إسأل<br />الصيدلي عن طريقة التخلص من الأدوية الغير مرغوب فيها فسوف تساعد هذه<br />الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>٦. معلومات إضافية.<br />&trade; ما هي مكونات ليڤوزال؟<br />&bull; المادة الفعالة هى ليفوستيريزين داي هيدروكلوريد.<br />كل قرص مغلف يحتوى على ٥ ملجم ليفوستيريزين داي هيدروكلوريد.<br />وثاني ،( PH &bull; المواد الأخرى هى : اللاكتوز اللامائي، سليلوز دقيق التبلور( 102<br />أكسيد السيليكون الغروية (أيروسيل ۲۰۰ )، ستيرات المغنيسيوم و أوبادري أبيض.<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>&trade; ما هو شكل أقراص ليڤوزال و ما هو محتوى العلبة؟<br />&trade; &bull; ليڤوزال ٥ ملجم أقراص مغلفة لونها مائل للأبيض ، دائرية ، محدبة الوجهين،<br />(JP محفور( 89 على جانب واحد ومستوية على الجانب الآخر.</p><p>ليڤوزال ٥ ملجم أقراص مغلفة ، متوفر فى عبوة تحتوي على ۲۰ قرص مغلف</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><img src="data:image/png;base64,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" alt="" width="816" height="1056" vspace="0" hspace="0" border="0" style="width:816px;height:1056px;margin-top:0px;margin-bottom:0px;margin-left:0px;margin-right:0px;border:0px solid black;" /></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            02/2013
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levozal 5 mg Film Coated tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each film-coated Tablet contains Levocetirizine Dihydrochloride 5 mg
Also contains 36.875 mg of lactose
For a full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.
Off-white, round, biconvex, about 7.0 mm in diameter, film coated tablets enqraved with 'JP89' on one side
and plain on other side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Levocetirizine 5 mg film-coated tablets are indicated in the symptomatic treatment of allergic rhinitis<br />(including persistent allergic rhinitis) and urticaria in adults and children aged 6 years and above.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><em><u>Posology</u></em></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Adults and adolescents 12 years and above</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The daily recommended dose is 5 mg (one film-coated tablet).</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Elderly:</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Adjustment of the dose is recommended in elderly patients with moderate to severe renal impairment (see Renal impairment below).</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Renal impairment:</u>The dosing intervals must be individualized according to renal function. Refer to the following table and adjust the dose as indicated. To use this dosing table, an estimate of the patient&#39;s creatinine clearance (CLcr) in ml/min is needed. The CLcr (ml/min) may be estimated from serum creatinine (mg/dl) determination using the following formula:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><img src="https://www.medicines.org.uk/emc/images/spc/spc~37217~2~165087.PNG" /></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Dosing adjustments for patients with impaired renal function:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><table cellspacing="0" cellpadding="2" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Group</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Creatinine clearance (ml/min)</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Dosage and frequency</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Normal</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">&ge; 80</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">1 tablet once daily</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Mild</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">50 &ndash; 79</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">1 tablet once daily</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Moderate</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">30 &ndash; 49</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">1 tablet once every 2 days</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Severe</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">&lt; 30</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">1 tablet once every 3 days</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">End-stage renal disease &ndash; Patients undergoing dialysis</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">&lt; 10</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Contra-indicated</p></td></tr></tbody></table><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In paediatric patients suffering from renal impairment, the dose will have to be adjusted on an individual basis taking into account the renal clearance of the patient and his body weight. There are no specific data for children with renal impairment.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Hepatic impairment</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">No dose adjustment is needed in patients with solely hepatic impairment. In patients with hepatic impairment and renal impairment adjustment of the dose is recommended (see Renal impairment above).</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Paediatric population</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><em>Children aged 6 to 12 years:</em></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The daily recommended dose is 5 mg (one film-coated tablet).</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">For children aged 2 to 6 years no adjusted dosage is possible with the film-coated tablet formulation. It is recommended to use a paediatric formulation of levocetirizine.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Method of administration</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The film-coated tablet must be taken orally, swallowed whole with liquid and may be taken with or without food. It is recommended to take the daily dose in one single intake.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Duration of use</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Intermittent allergic rhinitis (symptoms experienced for less than four days a week or for less than four weeks a year) has to be treated according to the disease and its history; it can be stopped once the symptoms have disappeared and can be restarted again when symptoms reappear. In case of persistent allergic rhinitis (symptoms experienced for more than four days a week or for more than four weeks a year), continuous therapy can be proposed to the patient during the period of exposure to allergens.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">There is clinical experience with the use of levocetirizine for treatment periods of at least 6 months. In chronic urticaria and chronic allergic rhinitis, there is clinical experience of use of cetirizine (racemate) for up to one year.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance, to cetirizine, to hydroxyzine to any other piperazine or to any of
the other excipients listed in section 6.1.
Severe renal impairment at less than 10 ml/min creatinine clearance.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Precaution is recommended with concurrent intake of alcohol (see section 4.5).</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Caution should be taken in patients with predisposing factors of urinary retention (e.g. spinal cord lesion, prostatic hyperplasia) as levocetirizine may increase the risk of urinary retention.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Caution should be taken in patients with epilepsy and patients at risk of convulsion as levocetirizine may cause seizure aggravation.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Response to allergy skin tests are inhibited by antihistamines and a wash-out period (of 3 days) is required before performing them.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Pruritus may occur when levocetirizine is stopped even if those symptoms were not present before treatment initiation. The symptoms may resolve spontaneously. In some cases, the symptoms may be intense and may require treatment to be restarted. The symptoms should resolve when the treatment is restarted.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Paediatric population</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The use of the film-coated tablet formulation is not recommended in children aged less than 6 years since this formulation does not allow for appropriate dose adaptation. It is recommended to use a paediatric formulation of levocetirizine</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">No interaction studies have been performed with levocetirizine (including no studies with CYP3A4 inducers); studies with the racemate compound cetirizine demonstrated that there were no clinically relevant adverse interactions (with antipyrine, pseudoephedrine, cimetidine, ketoconazole, erythromycin, azithromycin, glipizide and diazepam). A small decrease in the clearance of cetirizine (16%) was observed in a multiple dose study with theophylline (400 mg once a day); while the disposition of theophylline was not altered by concomitant cetirizine administration.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In a multiple dose study of ritonavir (600 mg twice daily) and cetirizine (10 mg daily), the extent of exposure to cetirizine was increased by about 40% while the disposition of ritonavir was slightly altered (-11%) further to concomitant cetirizine administration.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The extent of absorption of levocetirizine is not reduced with food, although the rate of absorption is decreased.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In sensitive patients, the concurrent administration of cetirizine or levocetirizine and alcohol or other CNS depressants may cause additional reductions in alertness and impairment of performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Pregnancy</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">There are no or limited amount of data (less than 300 pregnancy outcomes) from the use of levocetirizine in pregnant women. However, for cetirizine, the racemate of levocetirizine, a large amount of data (more than 1000 pregnancy outcomes) on pregnant women indicate no malformative or feto/ neonatal toxicity. Animal studies do not indicate direct or indirect harmful effects with respect to pregnancy, embryonal/fetal development, parturition or postnatal development (see section 5.3). The use of levocetirizine may be considered during pregnancy, if necessary.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Breast-feeding</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Cetirizine, the racemate of levocetirizine, has been shown to be excreted in human. Therefore, the excretion of levocetirizine in human milk is likely. Adverse reactions associated with levocetirizine may be observed in breastfed infants. Therefore, caution should be exercised when prescribing levocetirizine to lactating women.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Fertility</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">For levocetirizine no clinical data are available.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Comparative clinical trials have revealed no evidence that levocetirizine at the recommended dose impairs mental alertness, reactivity or the ability to drive.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Nevertheless, some patients could experience somnolence, fatigue and asthenia under therapy with Levocetirizine. Therefore, patients intending to drive, engage in potentially hazardous activities or operate machinery should take their response to the medicinal product into account.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Clinical studies</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Adults and adolescents above 12 years of age</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In therapeutic studies in women and men aged 12 to 71 years, 15.1% of the patients in the levocetirizine 5 mg group had at least one adverse drug reaction compared to 11.3% in the placebo group. 91.6 % of these adverse drug reactions were mild to moderate.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In therapeutic trials, the drop out rate due to adverse events was 1.0% (9/935) with levocetirizine 5 mg and 1.8% (14/771) with placebo.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Clinical therapeutic trials with levocetirizine included 935 subjects exposed to the medicinal product at the recommended dose of 5 mg daily. From this pooling, following incidence of adverse drug reactions were reported at rates of 1 % or greater (common: &ge;1/100 to &lt;1/10) under levocetirizine 5 mg or placebo:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><table cellspacing="0" cellpadding="2" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Preferred Term</strong></p><p style="margin-left:0px; margin-right:0px"><strong>(WHOART)</strong></p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Placebo</strong></p><p style="margin-left:0px; margin-right:0px"><strong>(n = 771)</strong></p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Levocetirizine 5mg</strong></p><p style="margin-left:0px; margin-right:0px"><strong>(n = 935)</strong></p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Headache</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">25 (3.2 %)</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">24 (2.6 %)</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Somnolence</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">11 (1.4 %)</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">49 (5.2 %)</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Mouth dry</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">12 (1.6 %)</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">24 (2.6 %)</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Fatigue</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">9 (1.2 %)</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">23 (2.5 %)</p></td></tr></tbody></table><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Further uncommon incidences of adverse reactions (uncommon&gt;1/1000 to&lt;1/100) like asthenia or abdominal pain were observed.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The incidence of sedating adverse drug reactions such as somnolence, fatigue, and asthenia was altogether more common (8.1 %) under levocetirizine 5 mg than under placebo (3.1%).</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Paediatric population</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In two placebo-controlled studies in paediatric patients aged 6-11 months and aged 1 year to less than 6 years, 159 subjects were exposed to levocetirizine at the dose of 1.25 mg daily for 2 weeks and 1.25 mg twice daily respectively. The following incidence of adverse drug reactions was reported at rates of 1% or greater under levocetirizine or placebo.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><table cellspacing="0" cellpadding="2" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>System Organ Class and Preferred Term</strong></p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Placebo (n = 83)</strong></p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Levocetirizine (n = 159)</strong></p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Gastrointestinal Disorders</strong></p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">&nbsp;</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Diarrhoea</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">0</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">3 (1.9 %)</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Vomiting</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">1 (1.2 %)</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">1 (0.6 %)</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Constipation</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">0</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">2 (1.3 %)</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Nervous System Disorder</strong></p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">&nbsp;</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Somnolence</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">2 (2.4 %)</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">3 (1.9 %)</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Psychiatric Disorders</strong></p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">&nbsp;</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">&nbsp;</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Sleep disorder</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">0</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">2 (1.3 %)</p></td></tr></tbody></table><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In children aged 6-12 years double blind placebo controlled studies were performed where 243 children were exposed to 5 mg levoceirizine daily for variable periods ranging from less than 1 week to 13 weeks. The following incidence of adverse drug reactions was reported at rates of 1 % or greater under levocetirizine or placebo.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><table cellspacing="0" cellpadding="2" border="1" style="width:691px"><tbody><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Preferred Term</strong></p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Placebo (n = 240)</strong></p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px"><strong>Levocetirizine (n = 243)</strong></p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Headache</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">5 (2.1 %)</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">2 (0.8 %)</p></td></tr><tr><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">Somnolence</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">1 (0.4 %)</p></td><td colspan="" rowspan="" style="border-color:#7b7b7b"><p style="margin-left:0px; margin-right:0px">7 (2. 9 %)</p></td></tr></tbody></table><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Post-marketing experience</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Adverse reactions from post-marketing experience are per System Organ Class and per frequency. The frequency is defined as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Immune system disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: hypersensitivity including anaphylaxis</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Metabolism and nutrition disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: increased appetite</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Psychiatric disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: aggression, agitation, hallucination, depression, insomnia, suicidal ideation, nightmare</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Nervous system disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: convulsion, paraesthesia, dizziness, syncope, tremor, dysgueusia</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Ear and labyrinth disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: Vertigo</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Eyes disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: visual disturbances, blurred vision, oculogyration</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Cardiac disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: palpitations, tachycardia</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Respiratory, thoracic, and mediastinal disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: dyspnoea</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Gastrointestinal disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: nausea, vomiting, diarrhoea</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Hepatobiliary disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: hepatitis</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><strong>&bull;&nbsp;</strong>Renal and urinary disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: dysuria, urinary retention</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Skin and subcutaneous tissue disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: angioneurotic oedema, fixed drug eruption, pruritus, rash, urticaria</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Musculoskeletal, connective tissues, and bone disorders:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: myalgia, arthralgia</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; General disorders and administration site conditions:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: oedema</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&bull; Investigations:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Not known: weight increased, abnormal liver function tests</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Description of selected adverse reactions</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">After levocetirizine discontinuation, pruritus has been reported.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">&nbsp;</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">To report any side effect(s):<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance and Drug Safety<br />Centre (NPC)<br />o Fax: +966-11-205-7662<br />o Call NPC at +966-11-2038222,<br />Ext: 2317-2356-2340.<br />o Reporting hotline: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: www.sfda.gov.sa/npc<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Symptoms</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Symptoms of overdose may include drowsiness in adults. In children, agitation and restlessness may initially occur, followed by drowsiness.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Management of overdoses</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">There is no known specific antidote to levocetirizine.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Should overdose occur, symptomatic or supportive treatment is recommended. Gastric lavage may be considered shortly after ingestion of the drug.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Levocetirizine is not effectively removed by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Pharmacotherapeutic group: Antihistamine for systemic use, piperazine derivatives, ATC Code: R06A E09.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Mechanism of action</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Levocetirizine, the (R) enantiomer of cetirizine, is a potent and selective antagonist of peripheral H1-receptors.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Binding studies revealed that levocetirizine has high affinity for human H1-receptors (Ki = 3.2 nmol/l). Levocetirizine has an affinity 2-fold higher than that of cetirizine (Ki = 6.3 nmol/l). Levocetirizine dissociates from H1-receptors with a half-life of 115 &plusmn; 38 min.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">After single administration, levocetirizine shows a receptor occupancy of 90% at 4 hours and 57% at 24 hours.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Pharmacodynamic studies in healthy volunteers demonstrate that, at half the dose, levocetirizine has comparable activity to cetirizine, both in the skin and in the nose.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Pharmacodynamic effects</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The pharmacodynamic activity of levocetirizine has been studied in randomised, controlled trials:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In a study comparing the effects of levocetirizine 5mg, desloratadine 5mg, and placebo on histamine-induced wheal and flare, levocetirizine treatment resulted in significantly decreased wheal and flare formation which was highest in the first 12 hours and lasted for 24 hours, (p&lt;0.001) compared with placebo and desloratadine.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The onset of action of levocetirizine 5 mg in controlling pollen-induced symptoms has been observed at 1 hour post drug intake in placebo controlled trials in the model of the allergen challenge chamber.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In vitro studies (Boyden chambers and cell layers techniques) show that levocetirizine inhibits eotaxin-induced eosinophil transendothelial migration through both dermal and lung cells. A pharmacodynamic experimental study&nbsp;<em>in vivo&nbsp;</em>(skin chamber technique) showed three main inhibitory effects of levocetirizine 5 mg in the first 6 hours of pollen-induced reaction, compared with placebo in 14 adult patients: inhibition of VCAM-1 release, modulation of vascular permeability and a decrease in eosinophil recruitment.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Clinical efficiency and safety</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The efficacy and safety of levocetirizine has been demonstrated in several double-blind, placebo controlled, clinical trials performed in adult patients suffering from seasonal allergic rhinitis or perennial allergic rhinitis, or persistent allergic rhinitis. Levocetirizine has been shown to significantly improve symptoms of allergic rhinitis, including nasal obstruction in some studies.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">A 6-month clinical study in 551 adult patients (including 276 levocetirizine-treated patients) suffering from persistent allergic rhinitis (symptoms present 4 days a week for at least 4 consecutive weeks) and sensitized to house dust mites and grass pollen demonstrated that levocetirizine 5 mg was clinically and statistically significantly more potent than placebo on the relief from the total symptom score of allergic rhinitis throughout the whole duration of the study, without any tachyphylaxis. During the whole duration of the study, levocetirizine significantly improved the quality of life of the patients.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In a placebo-controlled clinical trial including 166 patients suffering from chronic idiopathic urticaria, 85 patients were treated with placebo and 81 patients with levocetirizine 5mg once daily over six weeks. Treatment with levocetirizine resulted in significant decrease in pruritus severity over the first week and over the total treatment period as compared to placebo. Levocetirizine also resulted in a larger improvement of health-related quality of life as assessed by the Dermatology Life Quality Index as compared to placebo.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Chronic idiopathic urticaria was studied as a model for urticarial conditions. Since histamine release is a causal factor in urticarial diseases, levocetirizine is expected to be effective in providing symptomatic relief for other urticarial conditions, in addition to chronic idiopathic urticaria.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">ECGs did not show relevant effects of levocetirizine on QT interval.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Paediatric population</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The paediatric safety and efficacy of levocetirizine tablets has been studied in two placebo controlled clinical trials including patients aged 6 to 12 years and suffering from seasonal and perennial allergic rhinitis, respectively. In both trials, levocetirizine significantly improved symptoms and increased health-related quality of life.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In children below the age of 6 years, clinical safety has been established from several short- or long -term therapeutic studies:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">- one clinical trial in which 29 children 2 to 6 years of age with allergic rhinitis were treated with levocetirizine 1.25 mg twice daily for 4 weeks</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">- one clinical trial in which 114 children 1 to 5 years of age with allergic rhinitis or chronic idiopathic urticaria were treated with levocetirizine 1.25 mg twice daily for 2 weeks</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">- one clinical trial in which 45 children 6 to 11 months of age with allergic rhinitis or chronic idiopathic urticaria were treated with levocetirizine 1.25 mg once daily for 2 weeks</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">- one long-term (18 months) clinical trial in 255 levocetirizine - treated atopic subjects aged 12 to 24 months at inclusion</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The safety profile was similar to that seen in the short-term studies conducted in children 1 to 5 years of age.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The pharmacokinetics of levocetirizine are linear with dose- and time-independent with low inter-subject variability. The pharmacokinetic profile is the same when given as the single enantiomer or when given as cetirizine. No chiral inversion occurs during the process of absorption and elimination.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Absorption:</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Levocetirizine is rapidly and extensively absorbed following oral administration. In adults, Peak plasma concentrations are achieved 0.9 h after dosing. Steady state is achieved after two days. Peak concentrations are typically 270ng/ml and 308 ng/ml following a single and a repeated 5 mg o.d. dose, respectively. The extent of absorption is dose-independent and is not altered by food, but the peak concentration is reduced and delayed.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Distribution:</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">No tissue distribution data are available in humans, neither concerning the passage of levocetirizine through the blood-brain-barrier. In rats and dogs, the highest tissue levels are found in liver and kidneys, the lowest in the CNS compartment.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">In humans, levocetirizine is 90% bound to plasma proteins. The distribution of levocetirizine is restrictive, as the volume of distribution is 0.4 l/kg.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Biotransformation</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The extent of metabolism of levocetirizine in humans is less than 14% of the dose and therefore differences resulting from genetic polymorphism or concomitant intake of enzyme inhibitors are expected to be negligible. Metabolic pathways include aromatic oxidation, N- and O- dealkylation and taurine conjugation. Dealkylation pathways are primarily mediated by CYP 3A4 while aromatic oxidation involved multiple and/or unidentified CYP isoforms. Levocetirizine had no effect on the activities of CYP isoenzymes 1A2, 2C9, 2C19, 2D6, 2E1 and 3A4 at concentrations well above peak concentrations achieved following a 5 mg oral dose.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Due to its low metabolism and absence of metabolic inhibition potential, the interaction of levocetirizine with other substances, or vice-versa, is unlikely.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Elimination</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The plasma half-life in adults is 7.9 &plusmn; 1.9 hours. The half-life is shorter in small children.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The mean apparent total body clearance is 0.63 ml/min/kg. The major route of excretion of levocetirizine and metabolites is via urine, accounting for a mean of 85.4% of the dose. Excretion via feces accounts for only 12.9% of the dose. Levocetirizine is excreted both by glomerular filtration and active tubular secretion.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><em>Special population</em></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Renal impairment</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The apparent body clearance of levocetirizine is correlated to the creatinine clearance. It is therefore recommended to adjust the dosing intervals of levocetirizine, based on creatinine clearance in patients with moderate and severe renal impairment. In anuric end stage renal disease subjects, the total body clearance is decreased by approximately 80% when compared to normal subjects. The amount of levocetirizine removed during a standard 4-hour hemodialysis procedure was &lt; 10%.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Paediatric population:</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Data from a paediatric pharmacokinetic study with oral administration of a single dose of 5 mg levocetirizine in 14 children age 6 to 11 years with body weight ranging between 20 and 40 kg show that Cmax and AUC values are about 2-fold greater than that reported in healthy adult subjects in a cross-study comparison. The mean Cmax was 450 ng/ml, occurring at a mean time of 1.2 hours, weight-normalized, total body clearance was 30% greater, and the elimination half-life 24% shorter in this paediatric population than in adults. Dedicated pharmacokinetic studies have not been conducted in paediatric patients younger than 6 years of age. A retrospective population pharmacokinetic analysis was conducted in 323 subjects (181 children 1 to 5 years of age, 18 children 6 to 11 years of age, and 124 adults 18 to 55 years of age) who received single or multiple doses of levocetirizine ranging from 1.25 mg to 30 mg. Data generated from this analysis indicated that administration of 1.25 mg once daily to children 6 months to 5 years of age is expected to result in plasma concentrations similar to those of adults receiving 5 mg once daily.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Elderly</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Limited pharmacokinetic data are available in elderly subjects. Following once daily repeat oral administration of 30 mg levocetirizine for 6 days in 9 elderly subjects (65&ndash;74 years of age), the total body clearance was approximately 33% lower compared to that in younger adults. The disposition of racemic cetirizine has been shown to be dependent on renal function rather than on age. This finding would also be applicable for levocetirizine, as levocetirizine and cetirizine are both predominantly excreted in urine. Therefore, the levocetirizine dose should be adjusted in accordance with renal function in elderly patients.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Gender</u>:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">Pharmacokinetic results for 77 patients (40 men, 37 women) were evaluated for potential effect of gender. The half-life was slightly shorter in women (7.08 &plusmn; 1.72 hr) than in men (8.62 &plusmn; 1.84 hr); however, the body weight-adjusted oral clearance in women (0.67 &plusmn; 0.16 ml/min/kg) appears to be comparable to that in men (0.59 &plusmn; 0.12 ml/min/kg). The same daily doses and dosing intervals are applicable for men and women with normal renal function.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Race</u>:</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The effect of race on levocetirizine has not been studied. As levocetirizine is primarily renally excreted, and there are no important racial differences in creatinine clearance, pharmacokinetic characteristics of levocetirizine are not expected to be different across races. No race-related differences in the kinetics of racemic cetirizine have been observed.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Hepatic impairment:</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The pharmacokinetics of levocetirizine in hepatically impaired subjects have not been tested. Patients with chronic liver diseases (hepatocellular, cholestatic, and biliary cirrhosis) given 10 or 20 mg of the racemic compound cetirizine as a single dose had a 50% increase in half life along with a 40% decrease in clearance compared to healthy subjects.</p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px"><u>Pharmacokinetic / pharmacodynamic relationship</u></p><p style="margin-left:0px; margin-right:0px; text-align:start; text-indent:0px">The action on histamine-induced skin reactions is out of phase with the plasma concentrations.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated-dose toxicity, genotoxicity, carcinogenic potential or toxicity to reproduction.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose anhydrous<br />Microcrystalline Cellulose<br />Colloidal Silicone Dioxide<br />Magnesium Stearate<br />Opadry white</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                36 months
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not Store above 30&ordm;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Aluminium &ndash; Aluminium blister pack.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Company
Jeddah, Saudi Arabia.
Tel: +966-12-6081111, Fax: +966-12-6081222
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                04/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>